January 11, 2026

New Publication: From Sample to Mixed Reality: A Translational 3D MALDI Imaging Platform for Advanced 3D Spatial Omics Analysis of 3D Cell Culture Disease Models

New Publication: From Sample to Mixed Reality: A Translational 3D MALDI Imaging Platform for Advanced 3D Spatial Omics Analysis of 3D Cell Culture Disease Models

S. A. Iakab, J. Cordes, T. Enzlein, et al. “ From Sample to Mixed Reality: A Translational 3D MALDI Imaging Platform for Advanced 3D Spatial Omics Analysis of 3D Cell Culture Disease Models.” Adv. Sci. (2025): e16098. https://doi.org/10.1002/advs.202516098

Abstract

Human 3D cell cultures, including spheroids and organoids, are essential biological models for translational pharmaceutical and biomedical research. However, their 3D analysis using 2D- matrix-assisted laser desorption/ionization (MALDI) imaging-based spatial metabolomics remains challenging, since end-to-end solutions for 3D-enabling sample preparation, 3D-data processing, 3D-rendering, and 3D-user interaction are lacking. Here, a 3D-MALDI imaging platform and resource that advances each of three pillars is presented: i) the sample preparation introduces custom-designed molds for precise and reproducible embedding and cryosectioning of multiple spheroids and organoids, a substantial improvement over ad hoc or single-sample sectioning workflows; ii) the integrated computational framework that facilitates the generation of high-fidelity volumetric datasets that enable voxel-based analysis for feature discovery, surpassing traditional slice-based 2D analysis; iii) the mixed reality tool enables immersive spatial exploration of molecular distributions in 3D, extending user engagement beyond static 3D renderings. The versatility of the platform is illustrated by its translation to a clinical framework for the molecular profiling of patient-derived colon cancer organoids. Collectively, this integrated approach enables spatial metabolomic analysis in 3D, offers increased throughput, and paves the way for next-generation molecular diagnostics and personalized medicine applications.

Our latest News

discover more
Heidelberg University Hospital is a founding member of MEDI:CUS

Heidelberg University Hospital is a founding member of MEDI:CUS

MEDI:CUS is creating a shared digital infrastructure for the healthcare sector in Baden-Württemberg. As a founding member of MEDI:CUS e. V., Heidelberg University Hospital is actively contributing to its further development. Stephan Schulz-Gohritz, Chief Financial Officer of the Heidelberg and Mannheim University Hospitals Consortium, serves on the executive board of the newly founded association. Full […]

Enzymes in small beads for a more sustainable chemistry

Enzymes in small beads for a more sustainable chemistry

KIT Researchers Develop Customized Enzyme Beads for Flexible Industrial Biocatalysis Thanks to biocatalysis using enzymes, an enormous range of active pharmaceutical ingredients and other complex molecules can now be synthesized in an environmentally friendly manner. Researchers at the Karlsruhe Institute of Technology (KIT) have now developed a technology that allows enzymes to be assembled into […]

Universität Heidelberg with Top Placings in latest Shanghai Subject Ranking

Universität Heidelberg with Top Placings in latest Shanghai Subject Ranking

Clinical medicine in position 17 internationally, medical technology ranked 21 – three subjects take top place in Germany With clinical medicine and medical technology Heidelberg University is again among the best players in Medical Sciences worldwide. In the Global Ranking of Academic Subjects 2026 clinical medicine rose by one place over last year to rank […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp